Intermediate-risk acute myeloid leukemia therapy: current and future

Area of Science:

• Oncology
• Molecular Genetics
• Hematology

Background:

• Molecular genetics has revealed significant heterogeneity in acute myeloid leukemia (AML), especially in intermediate-risk patients.
• Current clinical practice primarily utilizes NPM1, CEBPA, and FLT3 markers for risk stratification.
• Standard treatment for intermediate-risk AML remains largely unchanged, with "3 + 7" induction therapy and cytarabine-based postremission therapy.

Purpose of the Study:

• To review the current landscape of intermediate-risk acute myeloid leukemia (AML) treatment.
• To highlight the impact of molecular genetics on understanding AML heterogeneity.
• To discuss the potential of novel therapeutic agents and personalized medicine in AML.

Main Methods:

• Review of current clinical practices and therapeutic standards for intermediate-risk AML.
• Analysis of the role of molecular markers in patient stratification and treatment selection.
• Examination of ongoing clinical development of novel targeted agents and immunoconjugates.

Main Results:

• The "3 + 7" induction regimen and cytarabine-based postremission therapy are standard but have limitations.
• Gemtuzumab ozogamicin shows potential for improving outcomes but lacks approval for this indication.
• Allogeneic stem cell transplantation offers survival benefits, with patient selection based on genetic profiles and transplant risks.

Conclusions:

• Despite advances in molecular profiling, personalized therapy for intermediate-risk AML is still evolving.
• Novel agents targeting specific leukemia drivers and pathways are under development.
• Comprehensive molecular profiling and innovative drug design hold promise for improving AML patient outcomes.